Endothelial dysfunction associated with oxidative stress in human.
暂无分享,去创建一个
[1] D. Pongratz,et al. Mitochondrial angiopathy in a family with MELAS. , 1992, Neuropediatrics.
[2] E. Stier,et al. Atherogenesis and cardiac death: are they related to dialysis procedure and biocompatibility? , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] N. Hoenich. Platelet and leucocyte behaviour during haemodialysis. , 1999, Contributions to nephrology.
[4] E. Schon,et al. Analysis of cybrids harboring MELAS mutations in the mitochondrial tRNALeu(UUR) gene , 1995, Muscle & nerve. Supplement.
[5] M. Leichsenring,et al. Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. , 1996, Kidney international.
[6] T. Coffman,et al. Angiotensin‐II receptors: new targets for antihypertensive therapy , 1997, Clinical cardiology.
[7] P. Vallance,et al. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. , 1999, Cardiovascular research.
[8] T. Lüscher,et al. Biology of the Endothelium , 1997, Clinical cardiology.
[9] D. Harrison,et al. Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.
[10] I. Nonaka,et al. Findings in muscle in complex I (NADH coenzyme Q reductase) deficiency , 1988, Annals of neurology.
[11] J. Cooke,et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. , 1999, Circulation.
[12] D. Collen,et al. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. , 1998, Atherosclerosis.
[13] M. Thomas,et al. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. , 1994, Free radical biology & medicine.
[14] J. Loscalzo,et al. Homocysteine and atherothrombosis. , 1998, The New England journal of medicine.
[15] T. Imaizumi,et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. , 2000, Circulation.
[16] B. Halliwell,et al. Biologically relevant metal ion‐dependent hydroxyl radical generation An update , 1992, FEBS letters.
[17] M. Miyata,et al. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. , 1995, Circulation.
[18] R. Foley,et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] D. Bagchi,et al. Oxidative mechanisms in the toxicity of metal ions. , 1995, Free radical biology & medicine.
[20] J. Keaney,et al. Antioxidants and atherosclerotic heart disease. , 1997, The New England journal of medicine.
[21] J. Himmelfarb,et al. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. , 1997, Journal of the American Society of Nephrology : JASN.
[22] G. Eknoyan,et al. Cardiovascular disease in chronic renal disease. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] Daniel Steinberg,et al. Low Density Lipoprotein Oxidation and Its Pathobiological Significance* , 1997, The Journal of Biological Chemistry.
[24] T. Imaizumi,et al. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. , 1999, Clinical science.
[25] L. Chiarantini,et al. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. , 1998, Kidney international.
[26] M. Gertler,et al. Ischemic Heart Disease: Insulin, Carbohydrate, and Lipid Interrelationships , 1972, Circulation.
[27] U. Förstermann,et al. Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III) , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] R. Sakuta,et al. Vascular involvement in mitochondrial myopathy , 1989, Annals of neurology.
[29] T. Lüscher,et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. , 1998, Circulation.
[30] T. Imaizumi,et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.
[31] S. Melov,et al. Mitochondrial disease in mouse results in increased oxidative stress. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[32] K. Kugiyama,et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins , 1990, Nature.
[33] J. Marx,et al. Iron, atherosclerosis, and ischemic heart disease. , 1999, Archives of internal medicine.
[34] C. Ronco,et al. Vitamin E-bonded membrane : a further step in dialysis optimization , 1999 .
[35] T. Tatemichi,et al. Cerebral Hyperemia in MELAS , 1994, Stroke.
[36] H. Drexler,et al. Endothelial dysfunction: clinical implications. , 1997, Progress in cardiovascular diseases.
[37] D. Stuehr. Structure-function aspects in the nitric oxide synthases. , 1997, Annual review of pharmacology and toxicology.
[38] T. Imaizumi,et al. Tetrahydrobiopterin restores endothelial function in long-term smokers. , 2000, Journal of the American College of Cardiology.
[39] J. Sullivan. The iron paradigm of ischemic heart disease. , 1989, American heart journal.
[40] J. Heinecke. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. , 1998, Atherosclerosis.
[41] J P Cooke,et al. Nitric oxide synthase: role in the genesis of vascular disease. , 1997, Annual review of medicine.
[42] D. Celermajer,et al. Endothelial dysfunction: does it matter? Is it reversible? , 1997, Journal of the American College of Cardiology.